Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Erin Alwon"'
Autor:
Mike Gart, Lucio N. Gordan, Rushir J. Choksi, Daniel P. Petro, Jeffrey A. Scott, Prateesh Varughese, Erin Alwon, Robert E. Smith
Publikováno v:
Journal of Clinical Oncology. 40:e13510-e13510
e13510 Background: Broad molecular profile-based initiation of Tx in newly diagnosed NSCLC 4 (KF Mileham, Cancer Med, 2022) is advocated by NCCN guidelines. Despite this, Tx is often started prior to, and without knowledge of, an actionable oncogenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc42dbb4923d536d2e66d63d4630d10f
https://doi.org/10.1200/jco.2022.40.16_suppl.e13510
https://doi.org/10.1200/jco.2022.40.16_suppl.e13510
Autor:
Kathryn S. Kolibaba, Avani Joshi, Michael Forsyth, Erin Alwon, Hooman Beygi, James A. Sterchele, Gerard T. Kennealey
Publikováno v:
Therapeutic advances in hematology. 4(3)
Objectives: Bendamustine is a unique cytotoxic agent active against various human malignancies, including chronic lymphocytic leukemia (CLL). In vitro studies suggest that cytotoxic activity of bendamustine on CLL-derived cells is synergized by ritux
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c22f8168e70e6b394c2746819918729
https://pubmed.ncbi.nlm.nih.gov/23730494
https://pubmed.ncbi.nlm.nih.gov/23730494
Autor:
Gerard T. Kennealey, Avani Joshi, James A. Sterchele, Kathryn S. Kolibaba, Erin Alwon, Michael Forsyth, Hooman Beygi
Publikováno v:
Blood. 118:3914-3914
Abstract 3914 Background Bendamustine is a unique, well-established alkylating agent with multifaceted actions leading to cancer cell death in several hematologic malignancies. In a phase 3 trial in treatment-naïve patients with chronic lymphocytic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::291b37e0cd34f1f605e40f820c89d4b5
https://doi.org/10.1182/blood.v118.21.3914.3914
https://doi.org/10.1182/blood.v118.21.3914.3914